SREBF1 and prostate carcinoma: Similarly, Chen et al. conducted a study using a bone-cancer dual-targeting biomimetic nano-delivery system and demonstrated that siRNA targeting of SREBP-1 enhanced the therapeutic effect of docetaxel against bone-metastatic castration-resistant prostate cancer [37].